EICHORCondition: Renal Cell Carcinoma · Sponsor: Abramson Cancer Center at Penn Medicine
This is a non-randomized, open-label phase II study designed to estimate 12-month treatment-free survival rate following total consolidative metastasis-and-primary directed therapy (MPDT) among patients with partial response/stable disease after at least 6 months of immune checkpoint blockade-based therapy for metastatic clear cell RCC. The investigators hypothesize that patients who undergo total consolidative MPDT followed by systemic therapy discontinuation will have a 12-month treatment-free survival rate of 32% compared to a null hypothesis of 13%
This description comes directly from the study's public registry record.
Matthew Doyle · 610-357-6354 · Matthew.Doyle@Pennmedicine.upenn.edu
Naomi Haas, MD · 2156627615 · Naomi.Haas@pennmedicine.upenn.edu
Always discuss trial participation with your own doctor first.
| Abramson Cancer Center at University of Pennsylvania | Philadelphia, Pennsylvania, United States | — |
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06770855